Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doravirine vs Integrase Inhibitors on Atherosclerosis in HIV
NCT04820933Phase 1Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Mar 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of doravirine in human immunodeficiency virus infection (HIV) and dyslipidemia, sponsored by UT Southwestern Medical Center. Primary endpoints: High-Density Lipoprotein function at 12 weeks, Monocyte chemotaxis at 12 weeks and 1 more. Started Mar 2024; status: completed.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus infection (HIV)dyslipidemia
Beyond the preview
Go deeper on NCT04820933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04820933.